Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT05119296 is registered in ClinicalTrials.gov with Saad A Khan as lead sponsor.

NCT NCT05119296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05119296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Lead sponsor
Saad A Khan
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 15, 2022
Completion date
July 31, 2027
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer